KR102133015B1 - Health functional food composition for prevention of diabetes - Google Patents
Health functional food composition for prevention of diabetes Download PDFInfo
- Publication number
- KR102133015B1 KR102133015B1 KR1020180128824A KR20180128824A KR102133015B1 KR 102133015 B1 KR102133015 B1 KR 102133015B1 KR 1020180128824 A KR1020180128824 A KR 1020180128824A KR 20180128824 A KR20180128824 A KR 20180128824A KR 102133015 B1 KR102133015 B1 KR 102133015B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- lactobacillus
- composition
- health functional
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 28
- 230000036541 health Effects 0.000 title claims abstract description 20
- 235000013376 functional food Nutrition 0.000 title claims abstract description 17
- 230000002265 prevention Effects 0.000 title claims description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 86
- 241000894006 Bacteria Species 0.000 claims abstract description 27
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 25
- 244000298479 Cichorium intybus Species 0.000 claims abstract description 24
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 23
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 22
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 22
- 229940082787 spirulina Drugs 0.000 claims abstract description 22
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 244000075850 Avena orientalis Species 0.000 claims abstract description 19
- 235000007319 Avena orientalis Nutrition 0.000 claims abstract description 19
- 244000134540 Polymnia sonchifolia Species 0.000 claims abstract description 17
- 235000003406 Polymnia sonchifolia Nutrition 0.000 claims abstract description 17
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 17
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 17
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000000835 fiber Substances 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000004310 lactic acid Substances 0.000 claims abstract description 13
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 10
- 102000008186 Collagen Human genes 0.000 claims description 46
- 108010035532 Collagen Proteins 0.000 claims description 46
- 229920001436 collagen Polymers 0.000 claims description 46
- 235000012000 cholesterol Nutrition 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 17
- 239000011707 mineral Substances 0.000 claims description 17
- 239000003925 fat Substances 0.000 claims description 16
- 238000010521 absorption reaction Methods 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 229940088598 enzyme Drugs 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 210000000936 intestine Anatomy 0.000 claims description 11
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 11
- 235000013824 polyphenols Nutrition 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 9
- 229920002498 Beta-glucan Polymers 0.000 claims description 9
- 229920001202 Inulin Polymers 0.000 claims description 9
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 9
- 229940029339 inulin Drugs 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 235000014633 carbohydrates Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000007901 soft capsule Substances 0.000 claims description 7
- 229930002875 chlorophyll Natural products 0.000 claims description 6
- 235000019804 chlorophyll Nutrition 0.000 claims description 6
- 229910052804 chromium Inorganic materials 0.000 claims description 6
- 239000000576 food coloring agent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 108010053210 Phycocyanin Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 4
- 239000013522 chelant Substances 0.000 claims description 4
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 235000021283 resveratrol Nutrition 0.000 claims description 4
- 229940016667 resveratrol Drugs 0.000 claims description 4
- 235000021466 carotenoid Nutrition 0.000 claims description 3
- 150000001747 carotenoids Chemical class 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 229920001864 tannin Polymers 0.000 claims description 3
- 235000018553 tannin Nutrition 0.000 claims description 3
- 239000001648 tannin Substances 0.000 claims description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241001608472 Bifidobacterium longum Species 0.000 claims description 2
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 claims description 2
- 102000029816 Collagenase Human genes 0.000 claims description 2
- 108060005980 Collagenase Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 244000199866 Lactobacillus casei Species 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 2
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 102000057297 Pepsin A Human genes 0.000 claims description 2
- 108090000284 Pepsin A Proteins 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 102000005158 Subtilisins Human genes 0.000 claims description 2
- 108010056079 Subtilisins Proteins 0.000 claims description 2
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 2
- 229960002424 collagenase Drugs 0.000 claims description 2
- 229940073505 ethyl vanillin Drugs 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229940089491 hydroxycitric acid Drugs 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 229940017800 lactobacillus casei Drugs 0.000 claims description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 229940111202 pepsin Drugs 0.000 claims description 2
- 235000019419 proteases Nutrition 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- 229960001322 trypsin Drugs 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- 239000002699 waste material Substances 0.000 claims description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 240000008042 Zea mays Species 0.000 claims 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims 1
- 235000005487 catechin Nutrition 0.000 claims 1
- UQWIHFJXDRNUDP-UHFFFAOYSA-N chembl1206007 Chemical compound COC1=CC(S(O)(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S(O)(=O)=O)=CC=C12 UQWIHFJXDRNUDP-UHFFFAOYSA-N 0.000 claims 1
- 229950001002 cianidanol Drugs 0.000 claims 1
- 235000005822 corn Nutrition 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 30
- 239000008280 blood Substances 0.000 abstract description 30
- 235000000346 sugar Nutrition 0.000 abstract description 19
- 230000000291 postprandial effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 39
- 235000009200 high fat diet Nutrition 0.000 description 25
- 208000008589 Obesity Diseases 0.000 description 16
- 230000003078 antioxidant effect Effects 0.000 description 16
- 235000020824 obesity Nutrition 0.000 description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 15
- 239000003963 antioxidant agent Substances 0.000 description 15
- 235000006708 antioxidants Nutrition 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 230000009102 absorption Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 235000015263 low fat diet Nutrition 0.000 description 10
- 208000011775 arteriosclerosis disease Diseases 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 206010003210 Arteriosclerosis Diseases 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 102000015779 HDL Lipoproteins Human genes 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 229930003427 Vitamin E Natural products 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000011651 chromium Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000021769 Acute sensory ataxic neuropathy Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 244000294611 Punica granatum Species 0.000 description 4
- 235000014360 Punica granatum Nutrition 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 229940109529 pomegranate extract Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 229920002079 Ellagic acid Polymers 0.000 description 3
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 3
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000004132 ellagic acid Nutrition 0.000 description 3
- 229960002852 ellagic acid Drugs 0.000 description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 3
- 229940107187 fructooligosaccharide Drugs 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 240000005528 Arctium lappa Species 0.000 description 2
- 235000003130 Arctium lappa Nutrition 0.000 description 2
- 235000008078 Arctium minus Nutrition 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 240000007049 Juglans regia Species 0.000 description 2
- 235000009496 Juglans regia Nutrition 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000020234 walnut Nutrition 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 description 1
- 102000004146 ATP citrate synthases Human genes 0.000 description 1
- 108090000662 ATP citrate synthases Proteins 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 241000546193 Clusiaceae Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000593508 Garcinia Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- QCDLLIUTDGNCPO-AEMJNJESSA-N [(3ar,4s,9as,9br)-4-hydroxy-6-methyl-3-methylidene-2,7-dioxo-4,5,9a,9b-tetrahydro-3ah-azuleno[8,7-b]furan-9-yl]methyl 2-(4-hydroxyphenyl)acetate Chemical compound C=1([C@H]2C(C(C=1)=O)=C(C[C@H](O)[C@H]1C(=C)C(=O)O[C@@H]12)C)COC(=O)CC1=CC=C(O)C=C1 QCDLLIUTDGNCPO-AEMJNJESSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 description 1
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 당뇨병 예방용 건강기능식품 조성물에 관한 것으로서, (A) 귀리 식이섬유; (B) 가르시니아 캄보지아 추출 분말; (C) 동결건조야콘; (D) 건조효모; (E) 치커리화이버; (F) 스피루리나; 및 (G) 12종알파혼합유산균을 포함함으로써 혈중 콜레스테롤 수치 개선, 식후 혈당 상승 억제 및 체지방 감소 효과를 제공하는 것을 목적으로 한다.The present invention relates to a health functional food composition for preventing diabetes, (A) oat dietary fiber; (B) Garcinia cambogia extract powder; (C) lyophilized yacon; (D) dry yeast; (E) chicory fiber; (F) Spirulina; And (G) 12 kinds of alpha mixed lactic acid bacteria to improve blood cholesterol levels, to suppress postprandial blood sugar elevation and to reduce body fat.
Description
본 발명은 당뇨병 예방용 건강기능식품 조성물에 관한 것이다.The present invention relates to a health functional food composition for preventing diabetes.
당뇨병은 신체 내에서 혈당 조절에 필요한 인슐린의 분비나 기능 장애로 인해 발생된 고혈당을 특징으로 하는 대사성 질환이다. 당뇨병으로 인한 만성적 고혈당은 신체 각 기관의 손상과 기능 부전을 초래하게 되는데 특히, 망막, 신장, 신경에 나타나는 미세혈관 합병증과 동맥경화, 심혈관, 뇌혈관질환과 같은 거대 혈관 합병증을 유발하고 이로 인한 사망률을 증가시킨다. 한편 당뇨병의 발생과 경과에 대한 연구들에 의하면 혈당조절을 철저히 하면 합병증 발생률이 저하되고 또한 체중 감량이나 투약 등으로 당뇨병이 예방될 수 있는 것으로 나타났다.Diabetes mellitus is a metabolic disease characterized by hyperglycemia caused by dysfunction or secretion of insulin necessary to control blood sugar in the body. Chronic hyperglycemia due to diabetes causes damage and dysfunction of organs in the body. In particular, microvascular complications in the retina, kidneys, and nerves and macrovascular complications such as arteriosclerosis, cardiovascular and cerebrovascular diseases, and mortality rates Increases. On the other hand, studies on the incidence and progress of diabetes have shown that thorough blood sugar control can reduce the incidence of complications and prevent diabetes by weight loss or medication.
보건복지부에서 최근에 발표한 국민건강영양조사 결과보고에 의하면 만 30세 이상에서의 당뇨병 유병률은 11.9%(남자 13.6%, 여자 10.3%)이며, 나이에 따라 유병률이 증가되어, 70세 이상에는 10명중 약 3명(27.6%)이 당뇨병 유병자인 것으로 확인되었다. 또한 본인이 당뇨병 환자라는 것을 알고 있는 인지율은 74.3%, 당뇨병 환자임을 알고 치료 받고 있는 비율인 치료율이 65.9%, 실제로 치료 받아 잘 조절되고 있는 환자는 22.1%(유병자 기준)로서 이 결과는 당뇨병 관리조절의 문제점이 여전히 지속되고 있음을 보여주고 있다.According to the National Health and Nutrition Survey report recently published by the Ministry of Health and Welfare, the prevalence of diabetes among those over 30 is 11.9% (13.6% for men and 10.3% for women), and the prevalence increases with age. About 3 (27.6%) of the patients were confirmed to be diabetic. In addition, the cognitive rate of knowing that I am a diabetic is 74.3%, the rate of treatment, which is the rate of knowing that I am diabetic, is 65.9%, and 22.1% of patients who are well-controlled by treatment (based on prevalence). It shows that the problem of regulation still persists.
한편, 콜레스테롤이란 지방 성분의 일종으로 현재는 성인병을 일으키는 동맥 경화증의 원인 중 하나로 나쁜 의미로 많이 사용되고 있지만, 우리 몸이 유지되기 위해서 꼭 필요한 성분이다. 콜레스테롤은 우리 몸을 이루는 기본 단위인 세포의 세포막, 신경세포의 수초, 그리고 지단백을 구성하는 성분이며 스테로이드 호르몬과 담즙산을 만드는 원료가 되는 성분이다. 이러한 콜레스테롤이 전혀 없으면 사람은 생명을 유지할 수 없지만 콜레스테롤이 정상 수치보다 높을 때는 동맥 경화를 일으킨다.On the other hand, cholesterol is a kind of fat component, and it is currently used as a bad meaning as one of the causes of atherosclerosis that causes adult disease, but it is an essential component for maintaining our body. Cholesterol is a component that makes up the cell membrane of cells, the myelin sheath, and lipoproteins, which are the basic units that make up our body, and is the ingredient that makes steroid hormones and bile acids. Without this cholesterol, a person cannot sustain life, but when cholesterol is higher than normal, it causes arteriosclerosis.
콜레스테롤은 저밀도 지단백 콜레스테롤(low-density lipoproteincholesterol; LDL cholesterol), 고밀도 지단백 콜레스테롤(high-density lipoprotein cholesterol; HDL cholesterol), 그리고 중성지방(triglyceride)으로 분류될 수 있다. 이 중 저밀도 지단백 콜레스테롤은 동맥 경화를 일으키는 것과 밀접한 관련이 있는 것으로 알려져 있다. 이에 비해 고밀도 지단백 콜레스테롤은 높을수록 몸에 좋은 역할을 하고 있으며, 중성 지방은 주로 당뇨와 비만과 관련이 있다.Cholesterol can be classified into low density lipoprotein cholesterol (low-densityesterlipoproteincholesterol; LDL cholesterol), high density lipoprotein cholesterol (high-density lipoprotein cholesterol;glycHDL cholesterol), and triglyceride. Low-density lipoprotein cholesterol is known to be closely related to causing atherosclerosis. In contrast, the higher the density of high-density lipoprotein cholesterol, the better it is for the body, and triglycerides are mainly associated with diabetes and obesity.
콜레스테롤이 높다고 해서 몸에 특별한 증상은 없다. 그러나 이러한 고콜레스테롤이 수십 년간 지속이 되면 이로 인해 심근 경색이나 뇌졸중과 같은 혈관 질환을 일으키게 된다.High cholesterol does not cause any symptoms in the body. However, if these high cholesterol levels last for decades, this causes vascular diseases such as myocardial infarction or stroke.
한편, 체지방은 신체를 구성하는 지방조직으로서, 이 조직은 피하조직, 유선, 신장주위 등에 널리 분포하며 저장지방으로 에너지에 이용되는 것 외에 내장 보호와 체온 조절기능을 한다. 지방조직은 주로 지방세포와 물로 구성되며 성인은 약 6~25kg 정도이다. 지방 1kg은 약 7,300kcal의 에너지가 있다. 저장지방이 과잉으로 축적된 상태가 비만이고 비만에서는 합병증 예방 관점에서 체중보다 체지방의 양이 중요시된다.On the other hand, body fat is a fat tissue that makes up the body, and this tissue is widely distributed in the subcutaneous tissue, the mammary glands, and around the kidneys. Adipose tissue is mainly composed of fat cells and water, and adults are about 6~25kg . 1 kg of fat has an energy of about 7,300 kcal. Obesity is a condition in which excess storage fat is accumulated, and in obesity, the amount of body fat is more important than weight in view of preventing complications.
상술한 고혈당, 고콜레스테롤, 체지방 증가 등의 문제는 최근 현대인들이 겪고 있는 문제에 해당하며, 이러한 증상 및 질환을 예방하거나 치료할 수 있는 건강기능식품과 의약품에 관한 연구가 다수 수행되고 있다.The above-mentioned problems such as high blood sugar, high cholesterol, and body fat increase correspond to problems that modern people are experiencing recently, and research on health functional foods and medicines capable of preventing or treating these symptoms and diseases has been conducted.
이에, 본 발명의 발명자들은 고혈당, 고콜레스테롤, 체지방 증가 등의 증상을 예방 및 개선하기 위한 연구 끝에, 당뇨병 예방용 건강기능식품 조성물을 개발하였으며, 이를 통해 현대인들의 삶의 질 향상과 건강 증진에 도움이 되고자 한다.Thus, the inventors of the present invention developed a health functional food composition for preventing diabetes after research to prevent and improve symptoms such as high blood sugar, high cholesterol, and increased body fat, and through this, helped improve the quality of life and promote health of modern people I want to be
본 발명이 해결하고자 하는 과제는 혈중 콜레스테롤 수치를 저하시키고 식후 혈당 상승을 억제하며 체지방을 감소시켜 동맥 경화, 당뇨병, 비만 등의 질환을 예방하기 위한 당뇨병 예방용 건강기능식품 조성물을 제공하는 것이다.The problem to be solved by the present invention is to provide a health functional food composition for preventing diabetes to prevent diseases such as arteriosclerosis, diabetes, and obesity by reducing blood cholesterol level, suppressing blood sugar elevation after eating, and reducing body fat.
본 발명은 (A) 귀리 식이섬유;The present invention (A) oat dietary fiber;
(B) 가르시니아 캄보지아 추출 분말;(B) Garcinia cambogia extract powder;
(C) 동결건조야콘;(C) lyophilized yacon;
(D) 건조효모;(D) dry yeast;
(E) 치커리화이버;(E) chicory fiber;
(F) 스피루리나; 및(F) Spirulina; And
(G) 12종알파혼합유산균을 유효성분으로 포함하는 당뇨병 예방용 건강기능식품 조성물을 제공한다.(G) Provides a health functional food composition for preventing diabetes comprising 12 kinds of alpha-lactic acid bacteria as an active ingredient.
또한, 상기 조성물로 제조된 유기농 케일을 주 성분으로 하는 건강기능식품을 제공한다.In addition, it provides a health functional food having an organic kale prepared from the composition as a main component.
본 발명은 혈중 콜레스테롤 수치 개선과 식후 혈당 상승을 억제하는 효과가 있다.The present invention has an effect of improving blood cholesterol levels and suppressing blood sugar elevation after eating.
또한, 본 발명은 체지방을 감소시키는 효과가 있다.In addition, the present invention has an effect of reducing body fat.
이하, 본 발명에 대한 이해를 돕기 위해 본 발명을 더욱 상세하게 설명한다. 이때, 본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 아니 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.Hereinafter, the present invention will be described in more detail to aid understanding of the present invention. At this time, the terms or words used in the present specification and claims should not be interpreted as being limited to ordinary or dictionary meanings, and the inventor appropriately defines the concept of terms to describe his or her invention in the best way. Based on the principle that it can be done, it should be interpreted as a meaning and a concept consistent with the technical idea of the present invention.
본 발명은 당뇨병 예방용 건강기능식품 조성물에 관한 것으로서, 혈중 콜레스테롤 수치를 저하시키고 식후 혈당 상승을 억제하며 체지방을 감소시켜 동맥 경화, 당뇨병, 비만 등의 질환을 예방하는 것을 주 목적으로 한다.The present invention relates to a health functional food composition for preventing diabetes, the main purpose of which is to prevent diseases such as arteriosclerosis, diabetes, and obesity by reducing blood cholesterol levels, suppressing blood sugar elevation after eating, and reducing body fat.
구체적으로, 본 발명은 (A) 귀리 식이섬유;Specifically, the present invention (A) oat dietary fiber;
(B) 가르시니아 캄보지아 추출 분말;(B) Garcinia cambogia extract powder;
(C) 동결건조야콘;(C) lyophilized yacon;
(D) 건조효모;(D) dry yeast;
(E) 치커리화이버;(E) chicory fiber;
(F) 스피루리나; 및(F) Spirulina; And
(G) 12종알파혼합유산균을 유효성분으로 포함할 수 있으며, 이하, 각 구성 성분들에 대해 구체적으로 설명한다.(G) 12 kinds of alpha mixed lactic acid bacteria may be included as an active ingredient, hereinafter, each component will be described in detail.
(A) 귀리 식이섬유(A) Oat dietary fiber
본 발명은 유효성분으로서, 귀리 식이섬유를 포함할 수 있고, 상기 귀리 식이섬유는 베타글루칸을 다량함유하고 있어 혈당상승에 도움을 주고 심혈관계질환 예방에 도움을 줄 수 있다.The present invention, as an active ingredient, may include oat dietary fiber, the oat dietary fiber contains a large amount of beta-glucan can help increase blood sugar and help prevent cardiovascular disease.
귀리는 탄수화물(21.7%), 단백질(14.3%), 지방질 등과 무기질, 비타민을 함유하고 있다. 귀리의 단백질은 쌀의 2배 정도이며, 라이신 등의 필수 아미노산이 많이 들어있다. 귀리는 수용성 섬유질을 다량 함유하고 있는데, 이는 귀리 식이섬유로 명명될 수 있다. 귀리 식이섬유는 콜레스테롤을 감소시키고, 심혈관 질환을 예방하는 폴리페놀 등의 항산화 성분이 풍부해 성인병 예방에도 도움을 준다. 또한 귀리 속의 베타글루칸 성분은 우리 몸속에서 숙변을 제거하고 장 내 노폐물을 배출시키는 효능이 있어 다이어트에도 효과적이다. 또한, 귀리 식이섬유는 장내에서 식염과 결합하여 몸 밖으로 배출시켜 혈압이 올라가는 것을 막아 준다. 따라서 고혈압의 치료와 예방에 도움이 된다. 비만인 사람도 섬유질을 충분히 섭취하면 영양분의 소화와 흡수를 억제하면서 만복감을 주기 때문에 과식을 하지 않게 된다. 또 대장의 운동을 촉진시켜 변이 내장을 통과하는 시간을 짧게 하고 배변량을 증가시킨다. 배변이 원활해지므로 변비가 없어지고, 따라서 다이어트에 도움이 된다.Oats contain carbohydrates (21.7%), protein (14.3%), fats, minerals and vitamins. Oat protein is about twice that of rice, and contains a lot of essential amino acids such as lysine. Oats contain a large amount of water-soluble fiber, which can be called oat dietary fiber. Oat dietary fiber is rich in antioxidants, such as polyphenols, which reduce cholesterol and prevent cardiovascular disease. In addition, the component of beta-glucan in oats is effective in dieting because it has the effect of removing sucrose from our body and discharging waste products in the intestine. In addition, oat dietary fiber combines with salt in the intestine and discharges it out of the body, preventing blood pressure from rising. Therefore, it is helpful for the treatment and prevention of hypertension. Even obese people do not overeat because they give a feeling of fullness while suppressing digestion and absorption of nutrients when enough fiber is consumed. In addition, it promotes the movement of the large intestine, shortening the time for the mutant to pass through the intestines and increasing the amount of defecation. Constipation is eliminated because the bowel movement becomes smooth, and thus helps diet.
본 발명에 따른 귀리 식이섬유는 베타글루칸을 포함하는 것을 특징으로 한다. 베타글루칸(β-glucan)은 다당류의 일종이고, 효모의 세포벽, 버섯류, 곡류 등에 존재하는 물질이다. 면역증강작용을 가지고 있는 베타글루칸은 포도당 중합체로서 포도당 단위체가 1, 3위치에 β-글리코시드 결합을 기본 구조로 가지고 있으며, 포도당이 결합되는 위치에 따라 구조 및 물리 화학적 성질이 다르다.Oat dietary fiber according to the invention is characterized in that it comprises a beta-glucan. Beta-glucan (β-glucan) is a type of polysaccharide and is a substance present in yeast cell walls, mushrooms, and grains. Beta-glucan, which has an immune-enhancing effect, is a glucose polymer, and the glucose unit has a β-glycoside bond at the 1 and 3 positions as a basic structure, and the structure and physicochemical properties differ depending on the position where the glucose is bound.
베타글루칸은 암세포를 직접 공격하지 않고 비특이적 면역반응으로 인간의 정상 세포의 면역기능을 활성화시켜 암세포의 증식과 재발을 억제하고 대식세포(macrophage)를 활성화 시켜 암세포가 있는 체내로 들어가 여러 가지 사이토카인(Cytokine)의 분비를 촉진시킴으로써 면역세포인 T세포와 B세포의 면역기능을 활성화 시켜 준다. 이 외에도 베타글루칸은 혈당강하 및 혈중 콜레스테롤 감소 효과가 우수하며, 지질대사를 개선하여 체지방 형성과 축적을 억제함으로써 항 비만효과를 가지고 있다.Beta-glucan does not directly attack cancer cells, but activates the immune function of human normal cells through a non-specific immune response to suppress the proliferation and recurrence of cancer cells and activate macrophage to enter the body with cancer cells and enter various cytokines ( Cytokine) to promote the secretion of immune cells T cells and B cells to activate the immune function. In addition, beta-glucan has an excellent effect of reducing blood sugar and reducing cholesterol in the blood, and has an anti-obesity effect by inhibiting body fat formation and accumulation by improving lipid metabolism.
본 발명에 따른 귀리 식이섬유는 폴리페놀을 포함하는 것을 특징으로 한다. 벤젠고리(C6H6)의 수소 중 하나가 하이드록시기(-OH)로 치환된 물질을 페놀이라고 하는데, 하이드록시기를 2개 이상 갖고 있는 물질을 폴리페놀이라고 명명한다.Oat dietary fiber according to the invention is characterized by comprising a polyphenol. A substance in which one of the hydrogens of the benzene ring (C 6 H 6 ) is substituted with a hydroxyl group (-OH) is called phenol, and a substance having two or more hydroxyl groups is called polyphenol.
폴리페놀은 산화를 방지하는 작용, 즉 항산화 기능을 갖고 있다. 따라서, 폴리페놀은 생체 내에서 항산화제로 작용함으로써 유효활성산소를 제거하여 피부 노화 등을 예방하는 작용을 한다. 또한 폴리페놀은 콜레스테롤이 소화관으로 흡수되는 것을 막아 주기 때문에 혈중 콜레스테롤의 수치를 낮게 해 주는 작용도 한다.Polyphenols have an antioxidant function, that is, an antioxidant function. Therefore, polyphenols act as antioxidants in vivo to remove active free radicals, thereby preventing skin aging and the like. In addition, since polyphenols prevent the absorption of cholesterol into the digestive tract, it also acts to lower the level of cholesterol in the blood.
(B) 가르시니아 캄보지아 추출 분말(B) Garcinia cambogia extract powder
본 발명은 유효성분으로서, 가르시니아 캄보지아 추출 분말을 포함할 수 있고, 상기 가르시니아 캄보지아 추출 분말은 탄수화물이 지방으로 합성되는 것을 억제하여 체지방을 감소시키는 작용을 한다.The present invention, as an active ingredient, may include garcinia cambogia extract powder, the garcinia cambogia extract powder acts to reduce body fat by inhibiting the synthesis of carbohydrates into fat.
가르시니아 캄보지아 추출 분말은 Guttiferae과의 식물로서 인도 남서부에서 자생하는 열대 식물인 ‘가르시니아 캄보지아’ 열매의 껍질 부위를 사용하며, 껍질에는 기능성분인 hydroxycitric acid(이하 HCA)가 약 10~30% 함유되어 있다.Garcinia cambogia extract powder is a plant of the family Guttiferae and uses the skin part of'Garcinia cambogia', a tropical plant native to southwestern India, and contains about 10 to 30% of the functional ingredient hydroxycitric acid (hereinafter referred to as HCA). .
탄수화물을 과량 섭취하면 체내에서 지방으로 전환되어 축적되는데, (-)-HCA는 탄수화물이 지방으로 전환될 때 사용되는 효소(ATP-citrate lyase)의 활성을 억제하여 체중과 체지방량을 감소시키는 것으로 인체적용시험, 동물시험 및 시험관 시험을 통해서 확인되었다.When carbohydrates are consumed excessively, they are converted into fat in the body and accumulated. (-)-HCA reduces the body weight and body fat by inhibiting the activity of the enzyme (ATP-citrate lyase) used when carbohydrate is converted to fat. It was confirmed through testing, animal testing and in vitro testing.
(C) 동결건조야콘(C) Freeze-dried yacon
본 발명은 유효성분으로서, 동결건조야콘을 포함할 수 있고, 상기 동결건조야콘은 생야콘을 동결시킨 후에 기압을 낮춰서 고체 상태의 물이 기체로 승화할 수 있도록함으로써 생성될 수 있다. 이러한 동결건조방식을 이용하면 수분량이 감소하여 세균이나 효소가 작용할 수 없고 상온에서 식품을 오랫동안 보존할 수 있다. 또한 고온 건조 방식보다 영양분이나 세포 조직을 덜 손상시켜 향기, 맛 등이 잘 보존된 식품을 만들 수 있다.The present invention, as an active ingredient, may include lyophilized yacon, and the lyophilized yacon can be produced by lowering the air pressure after freezing the raw yacon so that solid water can sublimate into the gas. Using this freeze-drying method, the amount of moisture decreases, so bacteria or enzymes cannot work and food can be preserved at room temperature for a long time. In addition, it is possible to make foods well preserved in scent and taste by less damaging nutrients or cellular tissue than the high temperature drying method.
야콘에는 이눌린과 탄닌, 카테킨 성분이 다량 함유되어 있어 인슐린 분비를 촉진시켜 당뇨증상 완화 기능을 한다. 나아가, 이눌린과 탄닌, 카테킨 성분은 당분해효소인 알파글루코시다아제의 분해작용을 더디게 만들어 갑작스런 혈당상승을 억제한다. 또한, 야콘은 프락토올리고당이라는 천연 물질을 다량 함유하고 있는데 이는 장내 유익균인 비피더스균의 영양분이 되어 유익균을 증식시켜 장의 점막을 보호하고 배변 활동을 촉진한다. 또한 혈중 콜레스테롤 수치를 낮추는 폴리페놀이 풍부하다. 비타민류가 적게 들어있는 대신 식이섬유가 풍부하고 열량이 낮아 다이어트 식품으로 좋다.Yacon contains a large amount of inulin, tannin, and catecatechin components, which promote insulin secretion and relieve diabetes symptoms. Furthermore, inulin, tannin, and catecatechin components slow the decomposition of alpha-glucosidase, a glycolytic enzyme, to suppress a sudden rise in blood sugar. In addition, yacon contains a large amount of a natural substance called fructooligosaccharide, which becomes the nutrient of the bifidus bacteria, a beneficial bacteria in the intestine, proliferates the beneficial bacteria to protect the mucous membrane of the intestine and promotes bowel movement. It is also rich in polyphenols that lower blood cholesterol levels. Instead of containing fewer vitamins, it is good for diet foods because it is rich in dietary fiber and low in calories.
본 발명에 따른 동결건조야콘은 이눌린을 포함하는 것을 특징으로 한다. 이눌린은 전분이나 설탕과 같은 당분이지만, 인체에 흡수되는 일이 거의 없이 장내에서 발효 분해된다. 장내에서는 젤 형태로 되어 있으며 당질의 흡수를 방해한다. 또한 장내에서 분해되어 장의 선인균의 먹이가 되기 때문에 변비개선에도 도움을 준다.The lyophilized yacon according to the present invention is characterized by comprising inulin. Inulin is a sugar such as starch or sugar, but is hardly absorbed by the human body and decomposes in the intestine. It is in the form of a gel in the intestine and interferes with the absorption of sugar. In addition, it decomposes in the intestine and becomes a prey for intestinal intestinal bacteria, thus helping to improve constipation.
이눌린은 식물에 의해 만들어지는 천연 다당류의 일종이다. 주로 돼지 감자, 치커리, 민들레, 우엉 등의 뿌리와 뿌리 줄기에 축적된다. 이러한 이눌린은 인슐린 분비를 저하시키는 작용도 있어, 혈당치의 상승을 억제 할 수 있다.Inulin is a type of natural polysaccharide made by plants. It is mainly accumulated in the roots and rhizomes of pig potatoes, chicory, dandelion, and burdock. This inulin also has the action of lowering insulin secretion, and can suppress an increase in blood sugar level.
본 발명에 따른 동결건조야콘은 프락토올리고당을 포함하는 것을 특징으로 한다. 상기 프락토올리고당은 바나나, 양파, 아스파라거스, 우엉, 마늘, 벌꿀, 치커리 뿌리 등과 같은 채소나 버섯, 과일류 등에 포함되어 있는 천연 물질이다.The lyophilized yacon according to the present invention is characterized by comprising fructooligosaccharides. The fructooligosaccharide is a natural substance contained in vegetables, mushrooms, fruits, and the like, such as banana, onion, asparagus, burdock, garlic, honey, and chicory root.
프락토올리고당은 극히 소량이 위산에 의해 가수분해되어 과당과 포도당으로 흡수되며 거의 대부분은 소화효소에 의해 분해되지 않고 대장에서 장내 균에 의해 발효된다. 발효의 결과로 생성된 단쇄지방산은 장내 환경을 산성화하며, 장내 균이 사용할 수 있는 손쉬운 에너지원으로 작용한다. 따라서, 유해균은 감소되고 유익한 비피더스균 등이 현저히 증가되어 장내 균총이 변하게 된다. 프락토올리고당은 식이섬유와 달리 bulking agent가 아니므로 직접적으로 연동운동을 촉진시키지는 못하지만, 비피더스균의 성장 촉진과 더불어 osmotic laxative agent의 기능이 있으므로 간접적으로 장의 연동운동을 촉진시킬 수 있다.Fracto-oligosaccharides are hydrolyzed by gastric acid in a very small amount and absorbed into fructose and 도glucose. The short-chain fatty acid produced as a result of fermentation acidifies the intestinal environment and acts as an easy energy source that can be used by intestinal bacteria. Therefore, harmful bacteria are reduced and beneficial Bifidobacteria are significantly increased, and the intestinal flora is changed. Fracto-oligosaccharides, unlike dietary fiber, are not bulking agents, so they cannot directly promote peristalsis, but they can also indirectly promote intestinal peristalsis because they have the function of osmotic laxative agent along with the growth of bifidobacteria.
프락토올리고당은 칼슘의 흡수를 선택적으로 증진시키는 작용이 있다. 프락토올리고당은 대장 환경을 산성화하여 칼슘의 용해도를 증가시키고 세포사이의 공간(intercellular space)을 통한 단순 투과(simple dispersion)를 촉진시키며, 칼슘 결합 단백질(Ca-binding protein)의 합성을 유도하여 능동 투과(active transport) 또한 증가시키는 작용을 한다. 식품으로 섭취된 칼슘은 주로 십이지장에서 흡수되는 것으로 알려져 있으나, 프락토올리고당을 섭취하는 경우에는 대장을 통한 칼슘 흡수가 증가하는 것으로 보고되었다.Fructooligosaccharide has the effect of selectively enhancing the absorption of calcium. Fracto-oligosaccharides acidify the large intestine environment to increase the solubility of calcium, promote simple perfusion through the intercellular space, and induce the synthesis of Ca-binding protein, which is active Permeation (active transport) also acts to increase. Calcium consumed as food is known to be absorbed mainly in the duodenum, but when fructoligosaccharides are ingested, calcium absorption through the large intestine has been reported to increase.
본 발명에 따른 동결건조야콘은 폴리페놀을 포함하는 것을 특징으로 한다. 폴리페놀에 대한 상세한 설명은 전술하였다.The lyophilized yacon according to the present invention is characterized by comprising polyphenols. Detailed description of polyphenols has been given above.
(D) 건조효모(D) Dry yeast
본 발명은 유효성분으로서, 건조효모를 포함할 수 있고, 상기 건조효모는 부패하지 않게 저장할 수 있도록 건조시킨 효모이다. 생효모는 통풍건조함 속의 선반 위에 생효모를 깔고 약 30 ℃의 온도에서 8시간 정도 건조시키는 방법, 수평 방향으로 회전하는 건조통 속에서 약 18시간 통풍 건조시키는 방법 등을 통해 건조될 수 있다.The present invention, as an active ingredient, may include dry yeast, the dried yeast is dried so that it can be stored without decay. The bio-yeast may be dried by placing bio-yeast on a shelf in a ventilation drying box and drying it for about 8 hours at a temperature of about 30° C., or drying air for about 18 hours in a drying container rotating in a horizontal direction.
효모는 진핵세포 구조를 가진 고등 미생물로 빵, 맥주, 포도주 등을 만드는 데 사용되는 미생물이다. 곰팡이나 버섯 무리이지만 균사가 없고 광합성능이나 운동성도 가지지 않는 단세포 생물의 총칭이다.Yeast is a high-grade microbial organism with a eukaryotic cell structure and is a microbial organism used to make bread, beer, and wine. It is a generic term for single-celled organisms that have fungi and mushrooms, but do not have hyphae and do not have photosynthesis or mobility.
효모는 단백질, 비타민 B 복합체, 크롬 및 셀레늄 등의 미네랄을 포함한다. 그리고, 크롬은 포도당과 콜레스테롤 수치를 낮추는 효과가 있다. 크롬은 신체에서 탄수화물과 지용성 물질의 신진대사를 안정화하는 작용을 한다. 나아가, 효모는 세포 재생을 도와 면역 체계를 강화하는 데 도움을 주는 다당류를 포함한다. 그리고, 효모는 세균과 싸우는 대식세포를 지원한다. 또한, 효모는 피부미용에도 표과가 있는데, 이는 효모가 소화작용과 간 기능 및 신진대사를 향상해 셀레늄의 항산화 효과로 정장작용을 하기 때문이다.Yeast contains proteins, vitamin B complexes, minerals such as chromium and selenium. And, chromium is effective in lowering glucose and cholesterol levels. Chromium works by stabilizing the metabolism of carbohydrates and fat-soluble substances in the body. Furthermore, yeast contains polysaccharides that help cell regeneration and help strengthen the immune system. In addition, yeast supports macrophages that fight bacteria. In addition, yeast also has a skin blemish, because yeast improves digestion, liver function, and metabolism, and acts as an antioxidant effect of selenium.
(E) 치커리화이버(E) Chicory fiber
본 발명은 유효성분으로서, 치커리화이버를 포함할 수 있고, 상기 치커리화이버는 치커리의 식이섬유를 의미한다.The present invention, as an active ingredient, may include a chicory fiber, the chicory fiber means a dietary fiber of chicory.
치커리는 슈가로프, 트레비소, 라디치오, 치콘 등의 채소류를 통칭하는 말이다. 그만큼 치커리는 다양한 종류가 있으며, 종류에 따라 색과 모양이 다르다. 종류에 따라 맛도 조금씩 차이가 있지만, 일반적으로 치커리 특유의 씁쓰름한 맛을 갖고 있어 입맛을 돋우는 채소로 활용된다.Chicory is a collective term for vegetables such as sugar loaf, treviso, radicchio, and chicon. There are many different types of chicory, and depending on the type, the color and shape are different. Depending on the type, the taste also varies slightly, but in general, it has a unique bittersweet taste, so it is used as a vegetable that enhances the taste.
치커리는 수분(94%) 외에 탄수화물(2.7%), 단백질, 지질 등과 무기질, 다량의 비타민을 함유하고 있으며, 열량은 낮은 반면 식이섬유와 칼륨, 칼슘뿐 아니라 각종 무기질, 비타민이 풍부해 비만 등 각종 성인병 예방과 다이어트에 도움을 준다. 또한 쓴맛을 내는 인티빈(Intybin)이라는 성분을 함유하고 있어 소화 촉진은 물론 콜레스테롤 수치를 낮춰 심장 및 혈관계를 강하게 하며, 항산화 성분이 있어 노화와 항암 예방에도 도움이 된다. In addition to moisture (94%), chicory contains carbohydrates (2.7%), protein, lipids, minerals, and large amounts of vitamins, while it has low calories, while it is rich in dietary fiber, potassium, and calcium, as well as various minerals and vitamins. It helps prevent adult diseases and diet. In addition, it contains a component called Intybin that has a bitter taste, which promotes digestion and lowers cholesterol levels, strengthening the heart and vascular system, and has antioxidant properties that help prevent aging and anti-cancer.
치커리의 식이섬유는 장내 균총 개선 및 정장효과가 있다. 장내 세균 중 유익한 세균으로 알려진 비피더스균과 락토바실러스는 치커리 섭취를 늘릴경우 크게 그 수가 증가한다. 나아가, 치커리에 함유된 이눌린을 섭취하면 사람의 대장 내 메탄가스 생성량이 없어지고 젖산과 같은 유기산의 생성량이 증가한다. 나아가, 치커리의 식이섬유를 섭취하면 장 내에서 콜레스테롤의 흡수가 감소한다. 이는 치커리 추출물이 콜레스테롤 재흡수를 방해하고 변으로 배설케함으로써 간장이나 혈액 내의 총 콜레스테롤 함량을 낮추는 요인으로 작용하고 있음을 나타낸다. 또한, 치커리 식이섬유를 섭취하면 포도당 흡수를 감소히켜 당뇨의 예방이나 치료에 효과가 있다. Chicory's dietary fiber improves intestinal microflora and has a formal effect. Among the bacteria in the gut, bifidus and Lactobacillus, which are known to be beneficial bacteria, increase significantly when chicory intake is increased. Furthermore, when inulin contained in chicory is ingested, the amount of methane gas generated in the large intestine of a person disappears, and the amount of organic acids such as lactic acid increases. Furthermore, eating chicory dietary fiber reduces cholesterol absorption in the intestine. This indicates that the chicory extract acts as a factor that lowers the total cholesterol content in the liver or blood by preventing cholesterol reabsorption and excreting it into the feces. In addition, eating chicory dietary fiber reduces glucose absorption, which is effective in preventing or treating diabetes.
(F) 스피루리나(F) Spirulina
본 발명은 유효성분으로서, 스피루리나를 포함할 수 있고, 상기 스피루리나는 지구에서 가장 오래된 조류로서 세포벽이 얇은 다세포 생물이다.The present invention, as an active ingredient, may include spirulina, the spirulina is the oldest algae in the earth, and is a multicellular organism with a thin cell wall.
스피루리나는 단백질, 탄수화물, 수용성 식이섬유를 비롯하여 항산화성 색소 성분(클로로필, 카로티노이드, 피코사이아닌), 항산화 효소(SOD) 및/또는 감마리놀렌산(GLA)을 포함한다. 나아가, 비타민으로는 베타카로틴, 비타민 B1, B2, B6, B12, 비타민 E, 이노시톨 및/또는 엽산을 포함한다. 또한, 스피루리나는 칼슘, 철, 칼륨, 마그네슘, 아연, 망간, 셀레늄, 게르마늄 등 무기질 성분도 포함한다.Spirulina contains protein, carbohydrate, water-soluble dietary fiber, as well as antioxidant pigment components (chlorophyll, carotenoids, phycocyanin), antioxidant enzymes (SOD) and/or persimmon marinolenic acid (GLA). Furthermore, vitamins include beta-carotene, vitamins B1, B2, B6, B12, vitamin E, inositol and/or folic acid. In addition, spirulina also contains inorganic components such as calcium, iron, potassium, magnesium, zinc, manganese, selenium, and germanium.
스피루리나는 높은 비율의 단백질(69.5%)을 함유하고 있는 고단백 식품이며, 필수아미노산을 모두 균형 있게 함유한다. 또한 스피루리나는 다세포로 세포벽이 없어 소화흡수율(95.1%)이 매우 높다.Spirulina is a high-protein food containing a high percentage of protein (69.5%) and contains all essential amino acids in a balanced manner. In addition, spirulina is a multicellular cell with no cell wall, so digestion and absorption rate (95.1%) is very high.
스피루리나의 색소 성분으로 황색의 카로티노이드, 녹색의 클로로필 및/또는 청색의 피코사이아닌을 포함한다. 피코사이아닌은 스피루리나에 함유되어 있는 담즙색소로서 지방의 소화를 도우며 항염 및 항산화성을 나타낸다. 또한 피코사이아닌은 토코페롤, 베타카로틴 등 항산화제를 다량 함유하고 있다. 클로로필는 엽록소를 의미하고 엽록소에 대한 효능은 전술하였다.Spirulina pigment components include yellow carotenoids, green chlorophylls and/or blue phycocyanins. Phycocyanin is a bile pigment contained in spirulina that helps digest fat and shows anti-inflammatory and antioxidant properties. In addition, phycocyanin contains large amounts of antioxidants such as tocopherol and beta-carotene. Chlorophyll means chlorophyll and its efficacy against chlorophyll is described above.
스피루리나는 당뇨병 환자에게 좋다. 당뇨병 환자의 체내에선 지방이 잘 연소되지 않아 지방을 에너지원으로 활용하는 데는 한계가 있다. 스피루리나는 단백질을 에너지원으로서 당뇨병 환자의 허기를 줄여주고 기운이 나게 하며 혈당 조절에도 도움을 준다. 또한 스피루리나는 적혈구수, 헤모글로빈 및 헤마토크리트을 개선시키므로 빈형증에도 효능이 있다. 나아가, 스피루리나에 함유되어 있는 단백질은 면역력 증강 효과가 있다. 또한, 콜레스테롤 저하, 면역증진, 항산화 기능 및/또는 체중 감소의 효능이 있으며, 스피룰리나는 풍부한 영양소와 높은 소화흡수율에 의해 영양 불량 개선에 효과가 있다. 또한 당뇨병, 빈혈, 췌장염, 간 질환, 위염, 위궤양, 백내장, 탈모증, 스트레스 등에 유효하며, 암 예방에도 도움이 된다.Spirulina is good for diabetics. There is a limit to using fat as an energy source because fat does not burn well in the body of diabetic patients. Spirulina is a protein source of energy, which reduces diabetes hunger, energizes and helps control blood sugar. Spirulina also improves red blood cell count, hemoglobin, and hematocrit, so it is also effective in anemia. Furthermore, the protein contained in Spirulina has an effect of enhancing immunity. In addition, it has the effect of lowering cholesterol, improving immunity, antioxidant function and/or weight, and spirulina is effective in improving malnutrition due to abundant nutrients and high digestion and absorption. In addition, it is effective for diabetes, anemia, pancreatitis, liver disease, gastritis, gastric ulcer, cataract, alopecia, stress, etc., and also helps prevent cancer.
(G) 12종알파혼합유산균(G) 12 kinds of alpha mixed lactic acid bacteria
본 발명은 유효성분으로서, 12종알파혼합유산균을 포함할 수 있다. 상기 12종알파혼합유산균은 Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus delbrueckii ssp. Bulgaricus, Lactobacillus fermentum, Streptococcus thermophiles, Bifidobacterium longum, Bifidobacterium breve 및 Bifidobacterium bifidum을 포함할 수 있다.The present invention, as an active ingredient, may include 12 kinds of alpha-lactic acid bacteria. The 12 alpha mixed lactic acid bacteria are Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus delbrueckii ssp. Bulgaricus, Lactobacillus fermentum, Streptococcus thermophiles, Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium bifidum.
이러한 12종알파혼합유산균은 장에 도달했을 때 유해균의 수를 감소시키고 유익균을 더욱 증식시켜 장내 환경을 건강하게 만드는 작용을 한다.These 12 kinds of alpha mixed lactic acid bacteria reduce the number of harmful bacteria when they reach the intestine and proliferate beneficial bacteria to make the intestinal environment healthy.
(H) 기타 성분(H) Other ingredients
본 발명의 조성물은 (A) 귀리 식이섬유; (B) 가르시니아 캄보지아 추출 분말; (C) 동결건조야콘; (D) 건조효모; (E) 치커리화이버; (F) 스피루리나; 및 (G) 12종알파혼합유산균 외에도, The composition of the present invention (A) oat dietary fiber; (B) Garcinia cambogia extract powder; (C) lyophilized yacon; (D) dry yeast; (E) chicory fiber; (F) Spirulina; And (G) 12 kinds of alpha-lactic acid bacteria,
비타민 E, 석류 추출물, 호장근 추출물, 갈근 추출물, 톳 추출물 및 킬레이트 콜라겐 펩타이드로 이루어지는 군에서 선택되는 하나 이상을 더 포함할 수 있다.It may further include one or more selected from the group consisting of vitamin E, pomegranate extract, walnut root extract, brown root extract, 톳 extract and chelated collagen peptide.
비타민 E(dl-alpha-Tocopheryl acetate)는 지용성 비타민으로 세포막을 유지시키는 역할을 하며 항산화 물질로 활성산소를 무력화시키는 효과가 있다.Vitamin E (dl-alpha-Tocopheryl acetate) is a fat-soluble vitamin that serves to maintain the cell membrane and has the effect of neutralizing free radicals with antioxidants.
즉 비타민 E는 세포막의 불포화지방산 사이에 존재하면서 불포화지방산의 과산화 작용이 진전되는 것을 막는 항산화제(antioxidant)로 작용한다. 항산화제 이론에 의하면 비타민 E는 세포막과 다른 세포 안의 작은 구조물(미토콘드리아, 마이크로솜, 리소솜 등)을 둘러싸고 있는 막에 모여 있으면서 막의 주요 구성 물질인 인지질이나 콜레스테롤과 접촉하게 된다. 또한 비타민 E는 면역 기능, 특히 T 림프구 기능의 정상화에도 필요하다.That is, vitamin E exists between the unsaturated fatty acids in the cell membrane and acts as an antioxidant that prevents the progress of the peroxidation of the unsaturated fatty acids. According to the antioxidant theory, vitamin E aggregates in the membrane surrounding the cell membrane and small structures (mitochondria, microsomes, lysosomes, etc.) in other cells, and comes into contact with phospholipids or cholesterol, the main constituents of the membrane. Vitamin E is also needed for normalization of immune function, especially T lymphocyte function.
따라서, 본 발명의 조성물은 비타민 E를 더 포함함으로써, 유해산소로부터 세포를 보호하는 항산화 효과를 극대화할 수 있으며, 이를 통해, 피부 및 모발, 혈관의 노화를 방지할 수 있는 효과가 있다.Therefore, the composition of the present invention may further include vitamin E, thereby maximizing the antioxidant effect of protecting cells from harmful oxygen, and through this, there is an effect of preventing aging of skin, hair, and blood vessels.
석류(Punica granatum L.)는 아시아 서남부, 인도 북서부 및 미국 캘리포니아의 자생 식물로서, 현재는 아열대 및 열대 각지에 널리 퍼져있는 식물이다. 예로부터 석류, 특히 적석류는 강장제로 알려져 왔으며, 특히 고혈압과 동맥경화 예방에 좋은 효과를 나타내는 것으로 알려져 있다.Pomegranate (Punica granatum L.) is a native plant in southwestern Asia, northwestern India, and California, the United States, and is now widely distributed in subtropical and tropical regions. Pomegranate, especially red pomegranate, has long been known as a tonic, and is known to exhibit good effects in preventing hypertension and arteriosclerosis.
석류 추출물(Pomegranate extract)은 비타민C1, B1, B2가 풍부해 피부 미용에 좋고 항산화 물질이 풍부하게 들어있어 노화 방지를 할 수 있다. 또 원활한 혈액순환을 돕기도 한다.Pomegranate extract is rich in vitamins C1, B1, and B2, which is good for skin beauty and rich in antioxidants, so it can prevent aging. It also helps smooth blood circulation.
또한, 석류 추출물은 식물성 에스트로겐이라 불리우는 엘라그산을 함유하고 있다. 엘라그산의 화학식은 C14H6O8 이고, 분자량은 302.19이다. 엘라그산은 폴리페놀 4개의 링으로 구성되어 있으며, 식물체 내에서는 전구물질인 엘라기타닌(ellagitannin) 형태로 존재한다.In addition, the pomegranate extract contains ellagic acid called phytoestrogens. The formula of ellagic acid is C 14 H 6 O 8 and the molecular weight is 302.19. Ellagic acid is composed of four rings of polyphenols, and is present in the form of precursor ellagitannin in plants.
따라서, 본 발명의 조성물은 석류 추출물을 더 포함함으로써, 항산화 효과 및 콜레스테롤 저하 효과를 극대화함으로써 피부 노화, 동맥 경화 등을 예방할 수 있는 효과가 있다.Therefore, the composition of the present invention further includes pomegranate extract, thereby preventing skin aging, arteriosclerosis, etc. by maximizing antioxidant and cholesterol lowering effects.
호장근 추출물(Polygonum cuspidatum extract)은 화학식은 C14H12O3이고 분자량은 228.25 인 레스베라트롤(resveratrol) 성분을 함유하고 있다.Polygonum cuspidatum extract has a chemical formula of C 14 H 12 O 3 and a resveratrol component with a molecular weight of 228.25.
레스베라트롤은 항암 및 강력한 항산화 작용을 하는 성분으로서, 혈청 콜레스테롤을 낮춰 주는 역할을 한다 이 외에도 항바이러스(antiviral), 신경보호작용(neuroprotective), 항염증작용(anti-inflammatory), 항노화(anti-aging) 및 수명을 연장시키는 효과 등이 있다. 프렌치 패러독스(French Paradox)는 레스베라트롤의 작용에 의한 것으로 프랑스인들이 비교적 지방이 많은 음식을 섭취하면서도 심장 질환의 발병률이 낮게 나타나는 현상을 말하는 것이다. Resveratrol is an anti-cancer and potent antioxidant that lowers serum cholesterol. In addition, anti-viral, neuroprotective, anti-inflammatory, and anti-aging ) And the effect of extending the life. French Paradox is caused by the action of resveratrol, and refers to a phenomenon in which the incidence of heart disease is low while French people eat relatively fatty foods.
따라서, 본 발명의 조성물은 호장근 추출물을 더 포함함으로써, 갱년기 여성의 피부 노화를 일으키는 활성 산소를 제거하여 피부 세포의 손상을 막고, 멜라닌 색소의 형성을 돕는 티로시나아제의 활성을 저해하여 색소 침착 예방과 같은 밝은 피부톤 유지에 도움을 줄 수 있으며, 산화방지제로서, 산화에 의해 본 발명의 조성물의 변질을 억제하는 역할을 할 수 있다.Therefore, the composition of the present invention further comprises a neutrophil extract, to prevent the damage of skin cells by removing free radicals that cause skin aging in menopausal women, and inhibit the activity of tyrosinase, which helps the formation of melanin pigments, thereby preventing pigmentation It can help maintain a bright skin tone, such as prevention, and as an antioxidant, may serve to suppress the deterioration of the composition of the present invention by oxidation.
갈근 추출물(Pueraria Lobata Root Extract)은 성갈근(칡뿌리)에서 추출하여 얻은 성분으로서, 식물성 에스트로겐으로 불리우는 다량의 플라보노이드 성분을 함유하고 있어 항산화 작용을 통해 피부 노화를 방지할 수 있으며, 여성 호르몬 불균형, 생리 불순 등 여성 질환에 효과가 있다. 혈관을 확장시키는 효능이 있어 고혈압을 낮춰 심장 질환을 예방할 수 있으며, 혈행 개선에 도움을 줄 수 있다.Pueraria Lobata Root Extract is a component obtained by extracting from sex root, and contains a large amount of flavonoids called phytoestrogens, which can prevent skin aging through antioxidant activity, female hormone imbalance, It is effective for women's diseases such as menstrual irregularities. It has the effect of expanding blood vessels, thereby preventing high blood pressure, preventing heart disease, and improving blood circulation.
따라서, 본 발명의 조성물은 갈근 추출물을 더 포함함으로써, 항산화 효과를 극대화할 수 있다.Therefore, the composition of the present invention can further maximize the antioxidant effect by further including a root extract.
톳 추출물(Hizikia Fusiforme Extract)은 비타민, 칼슘, 아연, 철분, 요오드 등의 미네랄이 풍부하며, 톳에 함유된 알긴산과 후코이단의 수용성 섬유소는 혈액 속 콜레스테롤 수치를 낮춰주고, 혈류 속도를 활발하게 함으로써, 혈관 질환을 예방할 수 있는 효과가 있으며, 각각 해독작용 및 항함작용에 효과가 있다. 또한, 칼슘과 마그네슘이 풍부하여 골다공증 예방에 탁월한 효과가 있으며, 칼로리가 낮고, 식이섬유가 풍부해, 다이어트에 도움이 된다.Iz Extract (Hizikia Fusiforme Extract) is rich in minerals such as vitamins, calcium, zinc, iron, and iodine, and the water-soluble fiber of alginic acid and fucoidan contained in 춰 lowers the cholesterol level in the blood and activates the blood flow rate, thereby promoting blood vessels. It is effective in preventing diseases, and is effective in detoxification and anti-hamming, respectively. In addition, it is rich in calcium and magnesium, which has an excellent effect in preventing osteoporosis, low calories, and rich in dietary fiber, which helps diet.
따라서, 본 발명의 조성물은 톳 추출물을 더 포함함으로써, 콜레스테롤 저하 효과를 극대화함으로써 동맥 경화 등의 혈관 관련 질환을 예방할 수 있는 효과가 있다.Therefore, the composition of the present invention further has an effect of preventing vascular-related diseases such as atherosclerosis by maximizing the cholesterol-lowering effect by further including the 톳 extract.
킬레이트 콜라겐 펩타이드는 피부 노화, 변색 및 열화 방지 효과가 있고, 피부의 수분함유량을 높여 보습성을 유지시키고 주름살 개선 효과를 제공한다. 또한, 제품의 보존성 또는 안정성이 우수하고, 피부 또는 체내에 콜라겐 펩타이드뿐 아니라 콜라겐 펩타이드에 킬레이트화된 미네랄의 흡수율이 우수한 효과가 있다.Chelate collagen peptide has the effect of preventing skin aging, discoloration and deterioration, and increases the moisture content of the skin to maintain moisturizing properties and provide wrinkle improvement effects. In addition, the product has excellent preservability or stability, and has an excellent effect of absorbing not only collagen peptides in skin or body, but also chelated minerals in collagen peptides.
본 발명의 킬레이트 콜라겐 펩타이드는 먼저 1) 콜라겐에 효소를 첨가하여 가수분해 반응시켜 콜라겐 펩타이드를 형성하는 것(본 발명에서 단계 1)은'콜라겐 나노화 단계' 라고도 한다.)을 특징으로 한다.The chelated collagen peptide of the present invention is characterized by first 1) adding an enzyme to collagen to hydrolyze it to form a collagen peptide (step 1 in the present invention is also referred to as a'collagen nanonization step').
콜라겐은 흔히 교원질이라고도 불리는 콜라겐(collagen)은 대부분의 동물, 특히 포유동물에서 많이 발견되는 섬유 단백질로, 피부와 연골 등 체내의 모든 결합 조직의 대부분을 차지한다. 콜라겐은 세 개의 폴리펩티드 사슬이 꼬여 있는 삼중나선형 구조를 가지고 있으며, 콜라겐의 평균 분자량은 30만 Da(Dalton, 달톤)으로 분자량이 큰 편이다.Collagen, also called collagen, is a fibrous protein found in most animals, especially mammals. It accounts for most of all connective tissue in the body, including skin and cartilage. Collagen has a triple helix structure in which three polypeptide chains are twisted, and the average molecular weight of collagen is 300,000 Da (Dalton, Dalton).
이와 같이 분자량이 큰 콜라겐이 체내에 흡수되기 위해서는 위장에서 소화시키는 과정이 선행되어야 하는 바, 본 발명의 킬레이트 콜라겐 펩타이드 제조방법은 빠른 체내 흡수를 위하여 효소를 첨가하여 상기 콜라겐을 가수분해 반응시켜 콜라겐 펩타이드로 분해하는 단계를 포함한다.In order for the collagen having such a large molecular weight to be absorbed into the body, the process of digestion in the stomach must be preceded. In the method for preparing the chelated collagen peptide of the present invention, the collagen peptide is hydrolyzed by adding enzymes for rapid absorption in the body. And disintegrating into.
본 발명의 콜라겐 펩타이드의 평균 분자량은 200 Da 내지 600 Da, 보다 구체적으로는 300 Da 내지 400 Da 이고, 그 사이즈는 0.1 nm 내지 10 nm, 보다 구체적으로는 1 nm 내지 5 nm 로 나노화되어 있는 바, 그 작은 분자량과 작은 크기로 인해 소화 과정 이전부터 체내 또는 피부에 빠르게 흡수되는 효과를 나타낸다.The average molecular weight of the collagen peptide of the present invention is 200 Da to 600 Da, more specifically 300 Da to 400 Da, and the size thereof is nanometered to 0.1 nm to 10 nm, more specifically 1 nm to 5 nm, Due to its small molecular weight and small size, it shows the effect of being quickly absorbed into the body or skin before the digestion process.
여기서, 상기 콜라겐 나노화 단계에 사용되는 효소는 단백질 분해효소로서, 콜라게나아제, 트립신, 파파인, 펩신 및 알칼라제로 이루어진 군에서 선택되는 1종 이상을 포함하는 것을 특징으로 하며, 콜라겐을 콜라겐 펩타이드로 분해하는 가수분해 반응은 50 ℃내지 70 ℃보다 구체적으로는 50 ℃내지 60 ℃에서 2 시간 내지 24 시간 동안 수행되는 것을 특징으로 한다.Here, the enzyme used in the collagen nanonization step is a protease, characterized in that it contains at least one selected from the group consisting of collagenase, trypsin, papain, pepsin and alcalase, and collagen is used as a collagen peptide. The hydrolysis reaction to decompose is characterized in that it is carried out for 2 to 24 hours at 50 ℃ to 60 ℃ more specifically than 50 ℃ to 70 ℃.
상기 범위의 온도 및 시간의 조건 하에 가수분해 반응이 일어나는 경우 체내 흡수율이 높은 적절한 분자량 및 크기의 콜라겐 펩타이드를 얻을 수 있다.When the hydrolysis reaction occurs under the conditions of temperature and time in the above range, it is possible to obtain a collagen peptide having an appropriate molecular weight and size with a high absorption rate in the body.
콜라겐 나노화 단계 이후, 본 발명은 2) 상기 콜라겐 펩타이드에 미네랄을 첨가하여 킬레이트 콜라겐 펩타이드를 형성하는 단계(본 발명에서 단계 2)는 '콜라겐 펩타이드 킬레이트화 단계'라고도 한다.)를 포함하는 것을 특징으로 한다.After the collagen nanonization step, the present invention is characterized in that 2) the step of forming a chelated collagen peptide by adding a mineral to the collagen peptide (step 2 in the present invention is also referred to as a'collagen peptide chelating step'). do.
본 발명에서 사용되는 미네랄은 Cu, Zn, Fe, Se, Cr, Mg, Mn 및 Co로 이루어진 군에서 선택되는 1종 이상의 수산화물 또는 황산화물인 것을 특징으로 하며, 아미노산의 말단기를 NH2+에서 NH3+로 하여 공유 결합을 이루어 주면서, COOH기의 H이온 대신 미네랄을 첨가하는 형태의 이온결합을 하여 안정화를 기한다.The mineral used in the present invention is characterized in that it is at least one hydroxide or sulfur oxide selected from the group consisting of Cu, Zn, Fe, Se, Cr, Mg, Mn and Co, and the terminal group of the amino acid is NH 2+ NH 3+ is used to form a covalent bond, and stabilizes by performing ion bonding in the form of adding minerals instead of H ions of the COOH group.
사용되는 미네랄은 콜라겐 펩타이드 100 중량 대비 1 내지 20 중량부인 것을 특징으로 하며, 상기 범위 내에서 미반응의 미네랄없이 킬레이트 콜라겐 펩타이드를 고순도로 얻을 수 있다. The mineral used is characterized in that it is 1 to 20 parts by weight based on 100 parts by weight of the collagen peptide, and within the above range, the chelated collagen peptide can be obtained with high purity without unreacted minerals.
킬레이트란, 금속이온과 배위결합을 하는 배위기를 1분자 내에 복수로 갖는 배위자가 금속과 배위결합했을 때의 결합, 또는 그 결합에 의하여 생성된 복합체를 의미한다. 본 발명에서는, 아미노산의 알파탄소에 결합된 아미노기의 공유결합에 참여하지 못한 비공유 전자쌍이 미네랄과 완전한 배위결합을 이루어 킬레이트 콜라겐 펩타이드를 형성하게 된다.Chelate refers to a bond formed when a ligand having a plurality of coordination bonds with a metal ion coordinates with a metal, or a complex produced by the bond. In the present invention, a non-covalent electron pair that does not participate in the covalent bond of the amino group bound to the alpha carbon of the amino acid forms a complete coordination bond with the mineral to form a chelated collagen peptide.
본 발명은 이러한 콜라겐 펩타이드와 미네랄의 킬레이트화를 통해 제품의 보존성 또는 안정성을 향상시킬 수 있으며, 체내 또는 피부에 콜라겐 펩타이드와 함께 미네랄의 흡수율도 개선하는 효과를 나타낼 수 있다.The present invention can improve the preservation or stability of the product through the chelating of these collagen peptides and minerals, and may exhibit an effect of improving the absorption rate of minerals with collagen peptides in the body or on the skin.
이후, 본 발명의 킬레이트 콜라겐 펩타이드 제조방법은 정제, 살균 및 건조 단계로 이루어진 군에서 선택되는 1 이상의 단계를 더 포함할 수 있다.Thereafter, the method for preparing a chelated collagen peptide of the present invention may further include one or more steps selected from the group consisting of purification, sterilization, and drying steps.
정제 단계를 통해 고순도의 킬레이트 콜라겐 펩타이드 제조할 수 있다. 정제 단계는 단계 1)의 콜라겐 나노화 단계에 의해 적절한 분자량 및 사이즈로 가수분해되지 않은 고분자량 또는 큰 사이즈의 콜라겐 펩타이드와 미반응의 효소 및 미네랄, 그리고 부산물 등을 여과 및 분리하여 이루어 질 수 있다.Through the purification step, high-purity chelate collagen peptides can be prepared. The purification step may be achieved by filtering and separating unreacted enzymes and minerals, and by-products of a high molecular weight or large-sized collagen peptide that is not hydrolyzed to an appropriate molecular weight and size by the collagen nanonization step of step 1).
또한, 물리적, 또는 화학적 처리를 통해 인체에 유해한 미생물을 제거할 수 있다. 내열성의 기구(유리기구, 도자기, 일부 금속제품 등)에 첨가하여 70℃ 내지 90 ℃에서 1 시간 5 시간 가열하여 유해 미생물, 세균들을 건열 살균할 수 있다.In addition, microorganisms harmful to the human body may be removed through physical or chemical treatment. It can be added to heat-resistant instruments (glassware, ceramics, some metal products, etc.) and heated at 70°C to 90°C for 1 hour and 5 hours to dryly sterilize harmful microorganisms and bacteria.
또한, 최종 제품의 유형에 따라 동결건조기 또는 분무 건조기를 이용한 건조 단계가 추가로 이루어 질 수도 있다.In addition, depending on the type of the final product, a drying step using a freeze dryer or a spray dryer may be additionally performed.
본 발명은 상기 킬레이트 콜라겐 펩타이드 제조방법에 의해 제조되고, 하기 화학식 1로 표시되는 킬레이트 콜라겐 펩타이드를 제공한다. The present invention provides a chelated collagen peptide prepared by the method for preparing a chelated collagen peptide, and represented by Chemical Formula 1 below.
(R은 아미노산의 종류를 결정짓는 곁사슬을 나타내고, M은 Cu, Zn, Fe, Se, Cr, Mg, Mn 및 Co 로 이루어진 군에서 선택되는 1종 이상이다.)(R represents a side chain that determines the type of amino acid, M is one or more selected from the group consisting of Cu, Zn, Fe, Se, Cr, Mg, Mn and Co.)
본 발명의 킬레이트 콜라겐 펩타이드는 식품, 의약품 또는 화장품에 사용될 수 있으며, 그 제형은, 분말, 정제, 과립제, 환제 등일 수 있다.The chelated collagen peptide of the present invention can be used in food, medicine or cosmetics, and the formulation can be powder, tablet, granule, pill, and the like.
본 발명의 킬레이트 콜라겐 펩타이드는, 1 시간, 보다 구체적으로는 30 분 이내에 킬레이트화된 미네랄과 함께 체내 또는 피부에 빠르게 흡수될 수 있는 바, 장 기간 섭취 또는 도포 시, 다른 콜라겐 제품에 비해 피부 보습, 탄력, 주름살 개선에서 탁월한 효과를 나타낼 수 있다.The chelated collagen peptide of the present invention can be rapidly absorbed into the body or skin with chelated minerals within 1 hour, more specifically 30 minutes, and when ingested or applied for a long period of time, the skin is moisturized compared to other collagen products, It can show excellent effect in improving elasticity and wrinkles.
또한, 본 발명의 조성물은 상기 유효성분 (A), (B), (C), (D), (E), (F) 및 (G)를 적절한 중량비로 포함하는 것을 특징으로 한다.In addition, the composition of the present invention is characterized in that it comprises the active ingredient (A), (B), (C), (D), (E), (F) and (G) in an appropriate weight ratio.
상기 조성물은, 조성물 100 중량부 기준으로, (A)는 40 내지 50 중량부, (B)는 10 내지 20 중량부, (C)는 15 내지 25 중량부, (D)는 20 내지 35 중량부, (E)는 5 내지 15 중량부, (F)는 5 내지 10 중량부, (G)는 5 내지 15 중량부를 포함할 수 있다.The composition, based on 100 parts by weight of the composition, (A) is 40 to 50 parts by weight, (B) is 10 to 20 parts by weight, (C) is 15 to 25 parts by weight, (D) is 20 to 35 parts by weight , (E) may include 5 to 15 parts by weight, (F) 5 to 10 parts by weight, and (G) 5 to 15 parts by weight.
각 구성 성분이 상기 범위 내로 포함되는 경우, 본 발명이 해결하고자 하는 식후 혈당 상승 억제, 혈중 콜레스테롤 개선 및 체지방 감소 등에 최적의 효과가 있을 수 있기 때문이다.This is because, if each component is included within the above range, the present invention may have optimal effects such as suppressing post-prandial blood sugar elevation, improving blood cholesterol, and reducing body fat.
또한, 본 발명은 상기 조성물을 포함하는 당뇨병 예방용 건강기능식품을 제공할 수 있으며, 상기 건강기능식품은 산제, 정제, 과립제, 환제, 경질캅셀제, 연질캅셀제 또는 액제 제형의 형태일 수 있다.In addition, the present invention can provide a health functional food for preventing diabetes comprising the composition, the health functional food may be in the form of powders, tablets, granules, pills, hard capsules, soft capsules or liquid formulations.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art to which the present invention pertains can easily practice. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein.
실시예 1Example 1
하기 표 1에 따라 당뇨병 예방용 건강기능식품 조성물을 제조하였다.A health functional food composition for preventing diabetes was prepared according to Table 1 below.
귀리 식이섬유 및 가르시니아 캄보지아 추출 분말을 주원료로 하여, 동결건조야콘, 건조효모, 치커리화이버, 스피루리나, 12종알파혼합유산균, 호장근 추출물 및 킬레이트 콜라겐 펩타이드를 부원료로 사용하였다.Oat dietary fiber and garcinia cambogia extract powder were used as the main raw materials, and lyophilized yacon, dried yeast, chicory fiber, spirulina, 12 kinds of alpha mixed lactobacillus, walnut root extract and chelated collagen peptide were used as auxiliary ingredients.
실시예 2Example 2
상기 실시예 1에서 제조된 조성물을 사용하여 하기 표 2에 따라 당뇨병 예방용 건강기능식품 연질캅셀을 제조하였다. 연질캅셀은 일반적인 연질캅셀 제조방법에 의하여 제조하였으며, 이 방법으로 본 발명의 기술적 범위가 이들로 제한되는 것은 아니다.Using the composition prepared in Example 1, according to Table 2 below, a health functional food soft capsule for preventing diabetes was prepared. The soft capsule was prepared by a general soft capsule manufacturing method, and the technical scope of the present invention is not limited to these methods.
실험예Experimental Example
상기 실시예 1에서 제조된 조성물을 이용하여 하기 각 효과에 대한 실험을 진행하였다.Experiments were performed for each of the following effects using the composition prepared in Example 1.
(1) 혈당 강하 효과(1) Blood sugar “lowering” effect
5주령 수컷 C57BL/6J 생쥐 총 28마리를 2개의 그룹으로 나누어 저지방 식이군에는 총 칼로리의 10%가 지방인 저지방 식이(제품 모델명 : D12450B; 공급사 : Research Diets, Inc., New Brunswick, NJ)를 4주간 투여하였고, 고지방 식이군에는 총 칼로리의 60%가 지방인 고지방 식이(제품 모델명 : D12492; 공급사 : Research Diets, Inc., New Brunswick, NJ)를 4주간 투여하였다. 이후, 저지방 식이군을 7마리씩 2개의 그룹(LFD, LFD-67)으로 나눈 후 LFD군에는 저지방 식이를 투여함과 동시에 생리식염수를 4.5주(31일)간 경구투여하고, LFD-67군에는 저지방 식이를 투여함과 동시에 실시예 1의 조성물을 4.5주(31일)간 경구투여한 후 다음날 실험을 종료하였다. 또한, 고지방 식이군도 7마리씩 2개의 그룹(HFD, HFD-67)으로 나눈 후 HFD군에는 고지방 식이를 투여함과 동시에 생리식염수를 4.5주(31일)간 경구투여하고, HFD-67군에는 고지방 식이를 투여함과 동시에 실시예 1의 조성물을 4.5주(31일)간 경구투여한 후 다음날 실험을 종료하였다. 실시예 1의 조성물의 경구투여 횟수는 1주일을 기준으로 6일이었다. 실험기간 동안 생쥐는 온도 20±2℃, 습도 50±5% 및 명암 주기(light-dark cycle) 12시간 단위의 사육실 환경하에서 사육되었다. 실험 종료일에 혈당, 혈장 인슐린, 혈장 내독소 및 분변 내독소의 함량을 측정하였다.A total of 28 5-week-old male C57BL/6J mice were divided into 2 groups, and the low-fat diet group had a low-fat diet (product model name: D12450B; supplier: Research Diets, Inc., New Brunswick, NJ). It was administered for 4 weeks, and the high-fat diet group was administered a high-fat diet (product model name: D12492; supplier: Research Diets, Inc., New Brunswick, NJ), which was 60% fat. Subsequently, the low-fat diet group was divided into two groups of 7 animals (LFD, LFD-67), and then the low-fat diet was administered to the LFD group and physiological saline was administered orally for 4.5 weeks (31 days), and the LFD-67 group. Simultaneously with the low-fat diet, the composition of Example 1 was orally administered for 4.5 weeks (31 days), and the experiment was terminated the next day. In addition, the high-fat diet group was divided into two groups (HFD, HFD-67) of 7 animals, followed by oral administration of physiological saline for 4.5 weeks (31 days) while administering a high-fat diet to the HFD group, and high fat in the HFD-67 group. At the same time as the diet was administered, the composition of Example 1 was orally administered for 4.5 weeks (31 days) and the experiment was terminated the next day. The number of oral administration of the composition of Example 1 was 6 days based on 1 week. During the experiment, mice were kept in a breeding room environment with a temperature of 20±2°C, a humidity of 50±5%, and a light-dark cycle of 12 hours. At the end of the experiment, the contents of blood glucose, plasma insulin, plasma endotoxin and fecal endotoxin were measured.
혈당은 생쥐 꼬리 끝에서 약 0.5㎕의 혈액을 채혈한 후 글루코오스 측정용 키트(제조사 : ASAN PHARM. CO. LTD, 대한민국)를 이용하여 측정하였다. 그림 1은 고지방 식이로 비만이 유도된 모델동물의 혈당 수준에 대해 실시예 1의 조성물이 미치는 영향을 실험군별로 나타낸 그래프이다. 아래 도면에서 보이는 바와 같이 고지방 식이 급여와 함께 실시예 1의 조성물을 투여한 군의 혈당 수준은 고지방 식이만을 급여한 군에 비해 유의적으로 감소하였다.Blood glucose was measured by using a glucose measuring kit (manufacturer: ASAN PHARM. CO. LTD, Korea) after collecting about 0.5 µl of blood from the tail of the mouse. Figure 1 is a graph showing the effect of the composition of Example 1 on the "glycemic" level of model animals in which obesity was induced by a high-fat diet for each experimental group. As shown in the figure below, the "blood glucose" level of the group administered with the composition of Example 1 along with the high fat diet was significantly decreased compared to the group fed only the high fat diet.
<그림 1><Picture 1>
혈장 인슐린은 mouse insulin ELISA kit(LINCO Research, St.Charles, MO)를 사용하여 측정하였다. 그림 2는 고지방 식이로 비만이 유도된 모델동물의 혈장 인슐린 수준에 대해 실시예 1의 조성물이 미치는 영향을 실험군별로 나타낸 그래프이다. 아래 도면에서 보이는 바와 같이 고지방 식이 급여와 함께 실시예 1의 조성물을 투여한 군의 혈장 인슐린 함량은 고지방 식이만을 급여한 군에 비해 유의적으로 낮게 나타났다.Plasma insulin was measured using a mouse insulin ELISA kit (LINCO Research, St.Charles, MO). Figure 2 is a graph showing the effect of the composition of Example 1 on the plasma insulin level of model animals in which obesity was induced by a high-fat diet for each experimental group. As shown in the figure below, the plasma insulin content of the group administered with the composition of Example 1 along with the high fat diet was significantly lower than that of the group fed only the high fat diet.
<그림 2><Picture 2>
그림 3은 고지방 식이로 비만이 유도된 모델동물의 혈장 내독소 함량에 대해 실시예 1의 조성물이 미치는 영향을 실험군별로 나타낸 그래프이다. 아래 도면에서 보이는 바와 같이 고지방 식이 급여와 함께 실시예 1의 조성물을 투여한 군의 혈장 내독소 함량은 고지방 식이만을 급여한 군에 비해 유의적으로 낮게 나타났다.Figure 3 is a graph showing the effect of the composition of Example 1 on the plasma endotoxin content of model animals in which obesity was induced by a high-fat diet for each experimental group. As shown in the figure below, the plasma endotoxin content of the group administered with the composition of Example 1 along with the high fat diet was significantly lower than that of the group fed only the high fat diet.
<그림 3><Picture 3>
(2) 체지방 감소 효과(항비만 효능)(2) Body fat reduction effect (anti-obesity effect)
5주령 수컷 C57BL/6J 생쥐 총 28마리를 2개의 그룹으로 나누어 저지방 식이군에는 총 칼로리의 10%가 지방인 저지방 식이(제품 모델명 : D12450B; 공급사 : Research Diets, Inc., New Brunswick, NJ)를 28일간 투여하였고, 고지방 식이군에는 총 칼로리의 60%가 지방인 고지방 식이(제품 모델명 : D12492; 공급사 : Research Diets, Inc., New Brunswick, NJ)를 28일간 투여하였다. 이후, 저지방 식이군을 7마리씩 2개의 그룹(LFD, LFD-67)으로 나눈 후 LFD군에는 저지방 식이를 투여함과 동시에 생리식염수를 31일간 경구투여하고, LFD-67군에는 저지방 식이를 투여함과 동시에 실시예 1의 조성물을 1×109 CFU의 양으로 31일간 경구투여한 후 다음날 실험을 종료하였다. 또한, 고지방 식이군도 7마리씩 2개의 그룹(HFD, HFD-67)으로 나눈 후 HFD군에는 고지방 식이를 투여함과 동시에 생리식염수를 31일간 경구투여하고, HFD-67군에는 고지방 식이를 투여함과 동시에 실시예 1의 조성물을 1×109 CFU의의 양으로 31일간 경구투여한 후 다음날 실험을 종료하였다. 실시예 1의 조성물의 경구투여 횟수는 7일을 기준으로 6일이었다. 실험기간 동안 생쥐는 온도 20±2℃, 습도 50±5% 및 명암 주기(light-dark cycle) 12시간 단위의 사육실 환경하에서 사육되었다. 실험 종료 후, 실험동물을 실험 동물을 심장천자(cardiac puncture)에 의해 희생시킨 후 부고환 지방조직(epididymal fat, EF)을 적출하여 무게를 측정하였다.A total of 28 5-week-old male C57BL/6J mice were divided into 2 groups, and the low-fat diet group had a low-fat diet (product model name: D12450B; supplier: Research Diets, Inc., New Brunswick, NJ). It was administered for 28 days, and the high-fat diet group was administered a high-fat diet (product model name: D12492; supplier: Research Diets, Inc., New Brunswick, NJ) with 28% of total calories fat. Thereafter, the low-fat diet group was divided into two groups of 7 animals (LFD, LFD-67), and then the low-fat diet was administered to the LFD group and physiological saline was administered orally for 31 days, and the low-fat diet was administered to the LFD-67 group. At the same time, the composition of Example 1 was orally administered for 31 days in an amount of 1 x 10 9 CFU, and the experiment was terminated the next day. In addition, the high-fat diet group was divided into two groups (HFD, HFD-67) of 7 animals, and then the high-fat diet was administered to the HFD group and physiological saline was administered orally for 31 days, and the high-fat diet was administered to the HFD-67 group. At the same time, the composition of Example 1 was orally administered for 31 days in an amount of 1 x 10 9 CFU, and the experiment was terminated the next day. The number of oral administration of the composition of Example 1 was 6 days based on 7 days. During the experiment, mice were kept in a breeding room environment with a temperature of 20±2°C, a humidity of 50±5%, and a light-dark cycle of 12 hours. After the end of the experiment, the experimental animal was sacrificed by cardiac puncture, and the weight was measured by extracting epididymal fat (EF).
그림 4는 고지방 식이로 비만이 유도된 모델동물의 체중 변화에 대해 실시예 1의 조성물이 미치는 영향을 실험군별로 나타낸 그래프이고, 그림 5는 고지방 식이로 비만이 유도된 모델동물의 체중 증가량에 대해 실시예 1의 조성물이 미치는 영향을 실험군별로 나타낸 그래프이다. 그림 4에서 아래 방향의 화살표는 실시예 1의 조성물을 경구투여한 시점을 나타낸다. 또한, 그림 5는 고지방 식이로 비만이 유도된 모델동물의 부고환 지방조직 무게 변화에 대해 실시예 1의 조성물이 미치는 영향을 실험군별로 나타낸 그래프이다. 아래 그림들에서 보이는 바와 같이 비만 유도 후 고지방 식이 급여와 함께 실시예 1의 조성물을 경구투여한 군의 경우 비만 유도 후 고지방 식이만을 급여한 군과 비교하였을 때 체중이 유의적으로 감소하였고, 지방조직의 무게도 더 낮게 나타났다.Figure 4 is a graph showing the effect of the composition of Example 1 on the weight change of a model animal in which obesity was induced by a high-fat diet for each experimental group, and Figure 5 is carried out on the weight gain of a model animal in which obesity was induced by a high-fat diet. It is a graph showing the effect of the composition of Example 1 for each experimental group. The arrow in the downward direction in Fig. 4 indicates the time point of oral administration of the composition of Example 1. In addition, Figure 5 is a graph showing the effect of the composition of Example 1 on the change in the weight of the epididymal adipose tissue of a model animal in which obesity was induced by a high fat diet for each experimental group. As shown in the figures below, in the case of a group in which the composition of Example 1 was orally administered with high fat diet after obesity induction, weight was significantly reduced when compared to the group in which only high fat diet was fed after induction of obesity, and adipose tissue The weight of it also appeared lower.
<그림 4><Figure 4>
<그림 5><Figure 5>
<그림 6><Figure 6>
(3) 혈중 콜레스테롤 감소 효과(혈장 중성지질, 혈장 총 콜레스테롤 및 혈장 HDL 콜레스테롤 함량 측정)(3) Blood cholesterol reduction effect (measurement of plasma neutral lipid, plasma total cholesterol and plasma HDL cholesterol content)
비만을 유도하고 35일간 유산균을 투여한 실험동물의 혈장 중성지질(plasma trigLyceride), 혈장 총 콜레스테롤(plasma cholesterol) 및 혈장 HDL 콜레스테롤(plasma HDL) 함량을 다음과 같이 측정하였다.Plasma trigLyceride, plasma total cholesterol and plasma HDL cholesterol (plasma HDL) content of experimental animals induced obesity and administered lactic acid bacteria for 35 days were measured as follows.
혈장 중성지질은 중성지질 측정용 키트(ASAN PHARM. CO. LTD, 대한민국)를 사용하여 측정하였다. 시험관에 효소용액 1.5㎖와 혈장 10㎕를 넣은 뒤 교반하였다. 이후, 중성지질의 함량이 각각 0, 75, 150, 225, 300 ㎎/㎗인 표준 용액과 함께 시료를 37℃의 수욕(water bath)에서 10분간 가온하고, 550㎚에서의 흡광도를 측정하여 비색 정량하였다. 또한, 혈장 총 콜레스테롤은 총 콜레스테롤 측정용 키트(ASAN PHARM. CO. LTD, 대한민국)를 사용하여 측정하였다. 시험관에 효소용액 1.5㎖와 혈장 10㎕를 넣은 뒤 교반하였다. 이후, 총 콜레스테롤의 함량이 각각 0, 75, 150, 225, 300 ㎎/㎗인 표준 용액과 함께 시료를 37℃의 수욕(water bath)에서 10분간 가온하고, 500㎚에서의 흡광도를 측정하여 비색 정량하였다. 또한, 혈장 HDL 콜레스테롤은 HDL 콜레스테롤 측정용 키트(ASAN PHARM. CO. LTD, 대한민국)를 사용하여 측정하였다. 혈장 50㎕에 침상시약 50㎕를 넣은 뒤 교반하고 실온에서 10 분간 방치한 후, 3000 rpm에서 10분간 원심분리하여 상층액 25㎕를 취하였다. 이후, 상층액에 효소용액 750㎕를 넣고 교반하였다. 이후, HDL 콜레스테롤의 함량이 각각 0, 10, 20, 30, 40, 50 ㎎/㎗인 표준 용액과 함께 시료를 37℃의 수욕(water bath)에서 5분간 가온하고, 500㎚에서의 흡광도를 측정하여 비색 정량하였다.Plasma neutral lipids were measured using a kit for measuring neutral lipids (ASAN PHARM. CO. LTD, Korea). Into the test tube, 1.5 ml of the enzyme solution and 10 µl of plasma were added and stirred. Subsequently, the sample was heated for 10 minutes in a water bath at 37° C. with a standard solution having a neutral lipid content of 0, 75, 150, 225, and 300 mg/mm 2, respectively, and the absorbance at 550 nm was measured to quantify colorimetry. Did. In addition, plasma total cholesterol was measured using a kit for measuring total cholesterol (ASAN PHARM. CO. LTD, Korea). Into the test tube, 1.5 ml of the enzyme solution and 10 µl of plasma were added and stirred. Subsequently, the samples were heated for 10 minutes in a 37° C. water bath with standard solutions having total cholesterol contents of 0, 75, 150, 225, and 300 mg/㎗, respectively, and colorimetric was measured by measuring absorbance at 500 nm. It was quantified. In addition, plasma HDL cholesterol was measured using an HDL cholesterol measurement kit (ASAN PHARM. CO. LTD, Korea). 50 μl of the needle reagent was added to 50 μl of plasma, stirred and left at room temperature for 10 minutes, followed by centrifugation at 3000 rpm for 10 minutes to obtain 25 μl of the supernatant. Thereafter, 750 µl of the enzyme solution was added to the supernatant and stirred. Subsequently, the samples were heated with a standard solution having HDL cholesterol content of 0, 10, 20, 30, 40, and 50 mg/mm 3 in a water bath at 37° C. for 5 minutes, and absorbance at 500 nm was measured. Colorimetric quantification.
또한, 혈장의 동맥경화지수(atherogenic index)을 하기의 식을 통해 계산하였다.In addition, the plasma arteriosclerosis index (atherogenic index) was calculated through the following equation.
동맥경화지수 = (총 콜레스테롤 - HDL 콜레스테롤) / HDL 콜레스테롤Arteriosclerosis index = (total cholesterol-HDL cholesterol) / HDL cholesterol
실험 결과, 비만 유도 후 고지방 식이 급여와 함께 실시예 1의 조성물을 경구투여한 군의 경우 비만 유도 후 고지방 식이만을 급여한 군과 비교하였을 때 혈장 중성지질, 혈장 총 콜레스테롤의 함량 및 동맥경화지수가 유의적으로 감소하였고, HDL 콜레스테롤 함량은 증가하는 결과를 보였다.As a result of the experiment, in the case of the group in which the composition of Example 1 was orally administered together with the high fat diet after induction of obesity, the plasma neutral lipid, the total cholesterol content and the arteriosclerosis index were compared to the group in which only the high fat diet after induction of obesity was fed. Significantly decreased, HDL cholesterol content showed an increase.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The above description of the present invention is for illustration only, and those skilled in the art to which the present invention pertains can understand that it can be easily modified to other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not restrictive.
Claims (5)
Hydroxycitric acid가 10 내지 30% 함유되어, 탄수화물이 지방으로 합성되는 것을 억제하여 체지방을 감소시키는, 가르시니아 캄보지아 추출 분말;
생야콘을 동결시킨 후 기압을 낮춰 고체 상태의 물을 기체로 승화할 수 있도록 함으로써 생성하여, 수분량이 감소하여 세균 및 효소가 작용할 수 없고 상온에서 오랫동안 보존할 수 있으며, 이눌린, 탄닌 및 카테킨 성분이 포함된, 동결건조야콘;
생효모를 통풍건조함 속의 선반위에 깔고 30 ℃의 온도에서 8시간 건조시키는 방법 또는 생효모를 수평방향으로 회전하는 건조통 속에서 18시간 통풍 건조시키는 방법으로 건조시킨, 건조효모;
인티빈 및 이눌린이 포함된, 치커리화이버;
69.5%의 단백질을 함유하고, 95.1%의 소화흡수율을 가지며, 클로로필, 카로티노이드 및 피코사이아닌을 포함하는, 스피루리나;
Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus delbrueckii ssp. Bulgaricus, Lactobacillus fermentum, Streptococcus thermophiles, Bifidobacterium longum, Bifidobacterium breve 및 Bifidobacterium bifidum을 포함하는, 12종알파혼합유산균;
레스베라트롤을 포함하는, 호장근 추출물; 및
빠른 체내 흡수를 위하여, 콜라겐에 콜라게나아제, 트립신, 파파인, 펩신 및 알칼라제 중 적어도 어느 하나의 단백질 분해효소를 첨가한 후, 50 ℃ 내지 60 ℃의 온도에서 2시간 내지 24시간 동안 가수분해 반응시켜, 평균 분자량은 300 Da 내지 400 Da 이고, 사이즈는 1 nm 내지 5 nm 로 나노화된 콜라겐 펩타이드를 형성한 후, 상기 콜라겐 펩타이드에 Cu, Zn, Fe, Se, Cr, Mg, Mn 및 Co 중 적어도 어느 하나의 미네랄을 상기 콜라겐 펩타이드 100 중량 대비 1 내지 20 중량부 첨가한 후, 내열성 기구에서 70℃ 내지 90 ℃에서 1시간 내지 5시간 가열하여 유해 미생물 또는 세균을 건열 살균한, 킬레이트 콜라겐 펩타이드;
를 유효성분으로 가진 조성물로서 구성되되,
조성물 100 중량부 기준으로,
상기 귀리 식이섬유는, 40.5 중량부;
상기 가르시니아 캄보지아 추출분말은, 20.5 중량부;
상기 동결건조야콘은, 5.7 중량부;
상기 건조효모는, 4.6 중량부;
상기 치커리화이버는, 6.8 중량부;
상기 스피루리나는, 5.5 중량부;
상기 12종알파혼합유산균은, 6.5 중량부;
상기 호장근 추출물은, 5.9 중량부;
상기 킬레이트 콜라겐 펩타이드는, 4 중량부;
로 구성되는 것을 특징으로 하는,
당뇨병 예방용 건강기능식품 조성물.It is rich in polyphenols that reduce cholesterol, prevent cardiovascular disease, and contains beta-glucan, which removes stool in the body and discharges waste products in the intestine. Oat dietary fiber;
Garcinia cambogia extract powder containing 10 to 30% of Hydroxycitric acid to reduce body fat by inhibiting the synthesis of carbohydrates into fats;
It is produced by freezing the raw corn and lowering the air pressure to allow the solid water to sublimate into gas, reducing the amount of moisture, preventing bacteria and enzymes from acting and preserving at room temperature for a long time, including inulin, tannin and catechin components. Lyophilized yacon;
A dry yeast placed on a shelf in a ventilation drying box and dried for 8 hours at a temperature of 30° C. or dried by drying for 18 hours in a drying container rotating in a horizontal direction;
Chicory fibers, including intivin and inulin;
Spirulina, which contains 69.5% protein, has a digestive absorption rate of 95.1%, and includes chlorophyll, carotenoids and phycocyanin;
Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus reuteri, Lactobacillus delbrueckii ssp. 12 kinds of alpha mixed lactic acid bacteria, including Bulgaricus, Lactobacillus fermentum, Streptococcus thermophiles, Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium bifidum;
Neutrophil extract, including resveratrol; And
For rapid absorption into the body, after adding at least one protease of collagenase, trypsin, papain, pepsin and alcalase to collagen, hydrolyze it for 2 to 24 hours at a temperature of 50 to 60°C. After reacting, the average molecular weight is 300 Da to 400 Da, and after forming a nanonized collagen peptide with a size of 1 nm to 5 nm, Cu, Zn, Fe, Se, Cr, Mg, Mn, and Co in the collagen peptide A chelate collagen peptide in which at least one mineral is added in an amount of 1 to 20 parts by weight based on 100 parts by weight of the collagen peptide, followed by heat sterilization of harmful microorganisms or bacteria by heating for 1 hour to 5 hours at 70°C to 90°C in a heat-resistant device;
It is composed of a composition having as an active ingredient,
Based on 100 parts by weight of the composition,
The oat dietary fiber, 40.5 parts by weight;
The garcinia cambogia extract powder, 20.5 parts by weight;
The lyophilized yacon, 5.7 parts by weight;
The dry yeast, 4.6 parts by weight;
The chicory fiber, 6.8 parts by weight;
The spirulina, 5.5 parts by weight;
The 12 kinds of alpha mixed lactic acid bacteria, 6.5 parts by weight;
The jangjanggeun extract, 5.9 parts by weight;
The chelated collagen peptide, 4 parts by weight;
Characterized by consisting of,
Health functional food composition for diabetes prevention.
상기 건강기능식품은, 연질캅셀제의 형태로 제조되되,
상기 연질캅셀은, 연질캅셀 100 중량부 기준으로,
젤라틴 68.850 중량부;
글리세린 21.862 중량부;
마나톨 8.197 중량부;
에틸 바닐린 0.164 중량부;
이산화티타늄 0.344 중량부;
식용 색소 청색 1호 0.004 중량부;
식용 색소 청색 3호 0.028 중량부;
식용 색소 적색 40호 0.551 중량부;
로 구성된 것을 특징으로 하는,
당뇨병 예방용 건강기능식품.In the health functional food containing the composition of claim 1,
The health functional food is prepared in the form of soft capsules,
The soft capsule, based on 100 parts by weight of soft capsule,
Gelatin 68.850 parts by weight;
Glycerin 21.862 parts by weight;
8.197 parts by weight of mannitol;
0.164 parts by weight of ethyl vanillin;
0.344 parts by weight of titanium dioxide;
Food coloring blue No. 1 0.004 parts by weight;
Food coloring blue 3 0.028 parts by weight;
Food coloring red No. 40 0.551 parts by weight;
Characterized by consisting of,
Health functional food for diabetes prevention.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180128824A KR102133015B1 (en) | 2018-10-26 | 2018-10-26 | Health functional food composition for prevention of diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180128824A KR102133015B1 (en) | 2018-10-26 | 2018-10-26 | Health functional food composition for prevention of diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200046959A KR20200046959A (en) | 2020-05-07 |
KR102133015B1 true KR102133015B1 (en) | 2020-07-10 |
Family
ID=70733193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180128824A KR102133015B1 (en) | 2018-10-26 | 2018-10-26 | Health functional food composition for prevention of diabetes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102133015B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102224928B1 (en) | 2019-11-26 | 2021-03-08 | 전남대학교산학협력단 | Leuconostoc mesenteroides subsp dextranicum NY203 strain, dietary fiber prepared by using the same and functional food composition comprising the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100195886B1 (en) * | 1996-11-01 | 1999-06-15 | 김상조 | Pharmaceutical composition for treating diabetes mellitus |
KR101199895B1 (en) | 2011-11-14 | 2012-11-09 | 권태동 | Pharmaceutical compositions for prevention and treatment of diabetes comprising natural mineral and lysate thereof as an active ingredient |
KR20180093488A (en) * | 2017-02-13 | 2018-08-22 | 동인당 주식회사 | Method for manufacturing JuksongwonCompuond-P through frement |
-
2018
- 2018-10-26 KR KR1020180128824A patent/KR102133015B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
비타민 A 부족 제 2형 당뇨를 부른다, 네이버 블로그. 2017.06.16. 공개, <URL: http://blog.naver.com/taeyang-zema/221030551381>* |
케일효능, 네이버 블로그. 2016.9.11. 공개, <URL: http://blog.naver.com/365star123/220809890594>* |
Also Published As
Publication number | Publication date |
---|---|
KR20200046959A (en) | 2020-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2335529T3 (en) | NEW BACTERIA THAT BELONGS TO THE GENERO BIFIDOBACTERIUM AND USE OF THE SAME. | |
CN105146614B (en) | A kind of functional calcium fruit ferment, enzyme beverage and its production method | |
JP4553604B2 (en) | Function enhancing composition for general food, health functional food or health supplement and method thereof | |
KR20070109981A (en) | Composition for body fat reduction | |
KR102315134B1 (en) | Fermented kiwi powder for improving bowel function and method of preparing the same | |
CN115074298A (en) | Probiotic composition with effects of resisting claustrophobia, protecting stomach and promoting digestion and eliminating stagnation and application thereof | |
CN106723087A (en) | A kind of tablet containing kelp dietary fiber and preparation method thereof | |
JP2008184383A (en) | Therapeutic or prophylactic agent for hyperlipemia and/or fatty liver | |
CN106690331A (en) | Kelp dietary fiber granules and preparation method thereof | |
KR20190088740A (en) | Antioxidant and anti-Obesity composition comprising Psyllium Husk and Kaempferia parviflora, formulatiom using the composition and preparing method thereof | |
CN102362627A (en) | Healthcare coffee containing cordyceps | |
WO2010035675A1 (en) | Immunopotentiator or antiallergic agent | |
KR20200076157A (en) | Composition for improving, treating or preventing intestinal function or inflammarory bowel disease comprising fermented rice as an active ingredient | |
JP5130593B2 (en) | Explosive fermented dietary fiber-containing composition | |
JP3644500B2 (en) | Method for producing mushroom lactic acid fermented liquid and mushroom lactic acid fermented liquid produced therefrom | |
JP2008074816A (en) | In vivo antioxidant | |
KR101133208B1 (en) | Method Manufacturing of Functional Fermented Soybean materials for improving the intestine function and constipation Using Plant?Originated Lactic Acid Bacteria and Bacillus | |
CN101766274A (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
KR102305931B1 (en) | A food composition for improving circulation of blood and increasing functions of immune comprising natural extracts | |
KR102133015B1 (en) | Health functional food composition for prevention of diabetes | |
CN108936607A (en) | Chronic Obstructive Pulmonary Disease full nutrition formula food | |
JP2008074801A (en) | Hepatoprotector | |
CN108523123A (en) | A kind of full nutritional support food of diabetes | |
KR20170106187A (en) | Antioxidant Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |